CUSTOM Study: Mevacor OTC Data May Be Boon For Switch Prospects
This article was originally published in The Pink Sheet Daily
Executive Summary
Former Nonprescription Drugs Advisory Committee Chair and J&J/Merck consultant Brass says Mevacor actual use study data support safe use of OTC lovastatin. Almost half of high-risk patients reported using the nonprescription statin after discussing it with a doctor.
You may also be interested in...
OTC Mevacor Label Illustrates New Approach Toward Approval
Over-the-counter Mevacor label features marked differences from J&J/Merck’s proposal for 10 mg lovastatin in 2000. More specific directions reflect 20 mg dose as well as narrower range of potential users; 30% of U.S. adults could be candidates for OTC statins, researcher says.
Savient Delays 10-Q Filing Due To Oxandrin Return Reserve Errors
The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.